Colorectal Cancer Trial, Recruiting NCT05536089 Sponsor: Singlera Genomics Inc. Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT05536089
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage I or stage II colorectal cancer (without high-risk features), confirmed by laboratory testing of tissue.
  • People aged 18 or older at the time of signing the consent form, of any gender.
  • People who are scheduled to have surgery to remove their colorectal cancer and who have a positive ctDNA blood test result (a test that detects small amounts of cancer DNA in the blood) before the surgery.
  • People who are generally well enough to carry out daily activities, based on a standard medical fitness scale (ECOG score of 0 or 1).
  • People who are able to give written consent themselves, or through a legal representative, and who are able to follow the study requirements.

Who may not be able to join:

  • People with a past history of colorectal cancer, non-cancerous growths in the colon (colorectal adenoma), or cancer of the digestive or upper airway tract.
  • People who have already received chemotherapy or other systemic cancer treatment before their scheduled surgery.
  • People who are currently pregnant or breastfeeding.
  • People who have a medical condition or other issue that, in the opinion of the study doctor, could affect the study results, prevent full participation, or make joining the trial not in their best interest.
  • People whose tumor tissue sample is not of sufficient quality or quantity to allow ctDNA testing to be carried out.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: KeFeng Ding, Ph.D, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: 13957117804

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Singlera Genomics Inc.
Registry
ClinicalTrials.gov
Start date
5 September 2022
Est. completion
1 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

5y DFS; ctDNA methylation markers versus CT/MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov